Evidence map›Paper›PMID 25362511›Full record

ArticleCurrent microbiology2015

Drotaverine hydrochloride degradation using cyst-like dormant cells of Rhodococcus ruber.

Irena B Ivshina, Anna N Mukhutdinova, Helena A Tyumina, Helena V Vikhareva, Nataliya E Suzina, Galina I El'-Registan, Andrey L Mulyukin

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Adaptive responses ofFrontiers in bioengineering and biotechnology · 2025
    Article
  3. Article
  4. ResistantMicroorganisms · 2024
    Article
  5. Removal of Phenol byMicroorganisms · 2024
    Article
  6. Microbiology · 2023
    Article
  7. Article
  8. Frontiers in microbiology · 2022
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Irena B IvshinaInstitute of Ecology and Genetics of Microorganisms, Russian Academy of Sciences, 13 Golev Street, 614081, Perm, Russia, ivshina@iegm.ru.
Anna N Mukhutdinova
Helena A Tyumina
Helena V Vikhareva
Nataliya E Suzina
Galina I El'-Registan
Andrey L Mulyukin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work has a focus on adaptive capabilities of the actinobacterium Rhodococcus ruber IEGM 326 to cope with drotaverine hydrochloride (DH), a known pharmaceutical pollutant. Cultivation of R. ruber in a nitrogen-limited medium with incubation at the ambient temperature resulted in the formation of cyst-like dormant cells (CLDCs). They maintained viability for 2-7 months, possessed the undetectable respiratory activity and elevated resistance to heating, and had a specific morphology. CLDCs are regarded to ensure long-term survival in various habitats and may be used as storage formulations. R. ruber IEGM 326 was tolerant to DH (MIC, 200 mg/l) and displayed different abilities to degrade this compound, depending on inoculum, temperature, and the presence of glucose as co-oxidized substrate. Thus, the loss of DH (20 mg/l) over 48 h at the optimal temperature (27 ± 2 °C) was 5-8 % in the absence of glucose after inoculating with vegetative cells. The addition of glucose (5 g/l) increased DH degradation up to 46 %. Noteworthy, CLDCs as inoculum were advantageous over vegetative cells to degrade DH at the non-optimal temperature (35 ± 2 °C) at reduced bulk respiratory activity. The obtained results are promising to improve the biodegrading capabilities of other Rhodococcus strains.

Indexed as

Biodegradation, EnvironmentalCulture MediaEnvironmental PollutantsPapaverineRhodococcusTemperatureCulture MediadrotaverinEnvironmental PollutantsPapaverine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.